EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Survival Impact of Programmed Cell Death Ligand‐1 Expression in Patients With Epithelial Ovarian Carcinoma

Achjima Tankul iD, Suchanan Hanamornroongruang iD, Naravat Poungvarin iD, Rachawalan Suriyasaengsri iD, Sompop Kuljarusnont iD, Pornprom Ittiamornlert iD, Wathirada Karnchanabanyong iD, Irene Ruengkhachorn iD, Saowalak Hunnangkul iD

Cancer Reports · 2026

DOI: 10.1002/cnr2.70636 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Reports, 2026. Verfasst von Achjima Tankul und 8 weiteren Autor:innen. Beteiligte Einrichtung: Gynecologic Oncology Division, Department of Obstetrics & Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, B7-H1 Antigen, Biomarkers, Tumor. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Siriraj Research Development Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To evaluate the proportion of expressed programmed cell death ligands‐1 (PD‐L1) in epithelial ovarian carcinoma patients, and the association with the clinicopathological, surgical outcomes, and oncologic outcomes. To compare PD‐L1 protein expression with messenger ribonucleic acid (mRNA) expression.

Methods

The patients who had pathology of epithelial ovarian/tubal/peritoneal carcinoma were enrolled. The demographic data, tumor characteristics, surgical outcomes, treatment details, and treatment response were analyzed by descriptive statistics. Spearman's rank correlation coefficient test was used to determine the correlation between protein expression and mRNA expression. The survival curve was developed utilizing the Kaplan‐Meier method, the log‐rank test was used to compare survival distributions of patients according to the PD‐L1 protein expression.

Results

A total of 100 patients, with high‐grade serous carcinoma being the most common subtype (42%). Advanced‐stage disease was present in 49% of patients, and 65% achieved optimal cytoreduction. PD‐L1 protein expression was detected in 23% of tumors, while the median normalized mRNA expression was 0.015 (IQR 0.004–0.037). A moderate positive correlation was observed between PD‐L1 protein and mRNA expression (Spearman's rho = 0.407, p < 0.001). The mean progression‐free survival (PFS) and overall survival (OS) were 44.32 ± 4.04 months and 74.19 ± 3.33 months, respectively.

Conclusions

PD‐L1 protein expression was observed in a minority of patients and was not significantly associated with survival outcomes. There was a moderate correlation between PD‐L1 protein and mRNA expressions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsCarcinoma, Ovarian EpithelialB7-H1 AntigenBiomarkers, TumorHumansFemaleMiddle AgedAgedRNA, MessengerCytoreduction Surgical ProceduresAdultPrognosisNeoplasm StagingRetrospective Studies

Stichwörter der Autor:innen

PD‐L1biomarkerscancerovarysurvival

Substanzen

B7-H1 AntigenCD274 protein, humanBiomarkers, TumorRNA, Messenger

Autor:innen und Institutionen

  • Gynecologic Oncology Division, Department of Obstetrics & Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Charoenkrung Pracharak Hospital, Bangkok, Thailand.
  • Department of Pathology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Department of Clinical Pathology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Division of Forensic Science Standard, Central Institute of Forensic Science, Bangkok, Thailand.
  • Division of Clinical Epidemiology, Department of Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

ORCID-Profile: Achjima Tankul, Suchanan Hanamornroongruang, Naravat Poungvarin, Rachawalan Suriyasaengsri, Sompop Kuljarusnont, Pornprom Ittiamornlert, Wathirada Karnchanabanyong, Irene Ruengkhachorn, Saowalak Hunnangkul

Förderung

  • Siriraj Research Development Fund

Zitieren

APA

Tankul, A., Hanamornroongruang, S., Poungvarin, N., Suriyasaengsri, R., Kuljarusnont, S., Ittiamornlert, P., Karnchanabanyong, W., Ruengkhachorn, I., & Hunnangkul, S. (2026). Survival Impact of Programmed Cell Death Ligand‐1 Expression in Patients With Epithelial Ovarian Carcinoma. Cancer Reports. https://doi.org/10.1002/cnr2.70636

Vancouver

Tankul A, Hanamornroongruang S, Poungvarin N, Suriyasaengsri R, Kuljarusnont S, Ittiamornlert P, et al. Survival Impact of Programmed Cell Death Ligand‐1 Expression in Patients With Epithelial Ovarian Carcinoma. Cancer Reports. 2026. doi:10.1002/cnr2.70636

BibTeX
@article{Tankul2026,
  author = {Tankul, Achjima and Hanamornroongruang, Suchanan and Poungvarin, Naravat and Suriyasaengsri, Rachawalan and Kuljarusnont, Sompop and Ittiamornlert, Pornprom and Karnchanabanyong, Wathirada and Ruengkhachorn, Irene and Hunnangkul, Saowalak},
  title = {Survival Impact of Programmed Cell Death Ligand‐1 Expression in Patients With Epithelial Ovarian Carcinoma},
  journal = {Cancer Reports},
  year = {2026},
  doi = {10.1002/cnr2.70636}
}
Kostenlos starten →